Answers are grounded in this paper and cite their sources.
Novel transducer measures electronic states in quantum dots, enabling sensitive biosensing for diseases.
High Resolution Image Download MS PowerPoint Slide We introduce a novel quantum transducer based on cadmium telluride quantum dots for reagentless and label-free biosensing. The device leverages the intrinsic electronic properties of quantum dot assemblies, as quantum conductance measurements directly reflect their quantum-capacitive (electronic) density-of-states according to the quantum-rate theory. This methodology is functionally analogous to scanning tunneling spectroscopy in its ability to map discrete electronic states (d I /d V ∝ d n /d E ), but operates in situ in an aqueous medium, making it ideal for electrochemical biosensing applications. By extracting quantum conductance G from admittance measurements (specifically G = ωC″ ), it provides a sensitive transducer signal, enabling accurate, in situ quantification of C-reactive protein−a key biomarker for cardiovascular and inflammatory disorders. This sensing assay delivers exceptional sensitivity, achieving a detection limit of 10.9 fM and a quantification limit of 36.2 fM in human serum. Our results establish a robust proof-of-concept for ultrasensitive, miniaturized, label-free electrochemical devices that exploit conductance-capacitance coupling in nanomaterials and their association with the electronic structure to diagnose a broad spectrum of infectious and noncommunicable diseases.
No takes yet. Share an insight, caveat, or question.
Garrote et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: